These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37274551)

  • 1. The impact of immigration on hepatitis B burden in the United States: a modelling study.
    Razavi-Shearer D; Gamkrelidze I; Pan CQ; Razavi-Shearer K; Blach S; Estes C; Mooneyhan E; Razavi H
    Lancet Reg Health Am; 2023 Jun; 22():100516. PubMed ID: 37274551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.
    Polaris Observatory Collaborators
    Lancet Gastroenterol Hepatol; 2023 Oct; 8(10):879-907. PubMed ID: 37517414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of hepatitis B elimination in high-income countries with ongoing immigration.
    Tian F; Feld JJ; Feng Z; Sander B; Wong WWL
    J Hepatol; 2022 Oct; 77(4):947-956. PubMed ID: 35483535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.
    Polaris Observatory HCV Collaborators
    Lancet Gastroenterol Hepatol; 2022 May; 7(5):396-415. PubMed ID: 35180382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.
    Polaris Observatory Collaborators
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):383-403. PubMed ID: 29599078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    European Union HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NIH consensus development statement on management of hepatitis B.
    Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
    NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review.
    Alberts CJ; Clifford GM; Georges D; Negro F; Lesi OA; Hutin YJ; de Martel C
    Lancet Gastroenterol Hepatol; 2022 Aug; 7(8):724-735. PubMed ID: 35576953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan: A simulation study.
    Tanaka J; Kurisu A; Ohara M; Ouoba S; Ohisa M; Sugiyama A; Wang ML; Hiebert L; Kanto T; Akita T
    Lancet Reg Health West Pac; 2022 May; 22():100428. PubMed ID: 35637862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus infection in immigrant populations.
    Coppola N; Alessio L; Pisaturo M; Macera M; Sagnelli C; Zampino R; Sagnelli E
    World J Hepatol; 2015 Dec; 7(30):2955-61. PubMed ID: 26730274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013.
    Degenhardt L; Charlson F; Stanaway J; Larney S; Alexander LT; Hickman M; Cowie B; Hall WD; Strang J; Whiteford H; Vos T
    Lancet Infect Dis; 2016 Dec; 16(12):1385-1398. PubMed ID: 27665254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tool to measure the economic impact of Hepatitis B elimination: A case study in Saudi Arabia.
    Sanai FM; Alghamdi M; Dugan E; Alalwan A; Al-Hamoudi W; Abaalkhail F; AlMasri N; Razavi-Shearer D; Razavi H; Schmelzer J; Alfaleh FZ
    J Infect Public Health; 2020 Nov; 13(11):1715-1723. PubMed ID: 32988769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Chronic Hepatitis B Virus Infection in the United States.
    Lim JK; Nguyen MH; Kim WR; Gish R; Perumalswami P; Jacobson IM
    Am J Gastroenterol; 2020 Sep; 115(9):1429-1438. PubMed ID: 32483003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019.
    Veracruz N; Gish RG; Cheung R; Chitnis AS; Wong RJ
    J Viral Hepat; 2022 May; 29(5):352-365. PubMed ID: 35274406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
    Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the national hepatitis B immunization program in China: a modeling study.
    Liu Z; Li M; Hutton DW; Wagner AL; Yao Y; Zhu W; Cao L; Tang S; Pan J; Wang Y; Zhao Q; Ren H; Wang Y; Wang W
    Infect Dis Poverty; 2022 Oct; 11(1):106. PubMed ID: 36221140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies.
    Li R; Shen M; Ong JJ; Cui F; Hu W; Chan P; Zou Z; Su S; Liu H; Zhang L; Seto WK; Wong WCW
    JHEP Rep; 2023 Oct; 5(10):100833. PubMed ID: 37675271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global prevalence of hepatitis C virus in children in 2018: a modelling study.
    Schmelzer J; Dugan E; Blach S; Coleman S; Cai Z; DePaola M; Estes C; Gamkrelidze I; Jerabek K; Ma S; Montoya S; Razavi-Shearer D; Razavi-Shearer K; Robbins-Scott S; Razavi H; El Sayed MH
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):374-392. PubMed ID: 31954439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted antiviral treatment of hepatitis B virus in culturally and linguistically diverse populations to achieve elimination targets in Australia.
    Taye BW; Valery PC; Clark PJ
    J Viral Hepat; 2022 Oct; 29(10):868-878. PubMed ID: 35748684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling the potential impact of global hepatitis B vaccination on the burden of chronic hepatitis B in the United States.
    Hutton DW; Toy M; Yang D; Zhang H; Handanagic S; Armstrong PA; Wasley A; Menzies NA; Pham H; Salomon JA; So SK
    J Viral Hepat; 2024 Oct; 31(10):614-622. PubMed ID: 39037155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.